252 related articles for article (PubMed ID: 16809735)
1. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
2. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
[TBL] [Abstract][Full Text] [Related]
3. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
Tsao CK; Moshier E; Seng SM; Godbold J; Grossman S; Winston J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2012 Mar; 10(1):15-20. PubMed ID: 22130294
[TBL] [Abstract][Full Text] [Related]
4. The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: preliminary results.
Varlotto JM; Gerszten K; Heron DE; Comerci J; Gautam S; Selvaraj R; Lalonde R; Chura JC
Am J Clin Oncol; 2006 Jun; 29(3):281-9. PubMed ID: 16755182
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature.
Benisovich VI; Silverman L; Slifkin R; Stone N; Cohen E
Cancer; 1996 Jan; 77(1):160-3. PubMed ID: 8630924
[TBL] [Abstract][Full Text] [Related]
7. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
8. A comparison of measured creatinine clearance versus calculated glomerular filtration rate for assessment of renal function before autologous and allogeneic BMT.
Hahn T; Yao S; Dunford LM; Thomas J; Lohr J; Arora P; Battiwalla M; Smiley SL; McCarthy PL
Biol Blood Marrow Transplant; 2009 May; 15(5):574-9. PubMed ID: 19361749
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
Schrier BP; Peters M; Barentsz JO; Witjes JA
Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
[TBL] [Abstract][Full Text] [Related]
10. Novel algorithm for more accurate calculation of renal function in adults with cancer.
Holweger K; Lipp HP; Dietz K; Hartmann JT; Bokemeyer C
Ann Pharmacother; 2008 Dec; 42(12):1749-57. PubMed ID: 19033483
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC].
Beuzeboc P; Dhote R; Thiounn N; Flam T; Zerbib M; Debré B; Pouillart P
Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
13. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
14. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
Rashid ST; Salman M; Agarwal S; Hamilton G
Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of urothelial tract cancer: Memorial Sloan-Kettering Cancer Center experience.
Yagoda A
Important Adv Oncol; 1988; ():143-59. PubMed ID: 3042602
[No Abstract] [Full Text] [Related]
17. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
Smilde TD; van Veldhuisen DJ; Navis G; Voors AA; Hillege HL
Circulation; 2006 Oct; 114(15):1572-80. PubMed ID: 17015793
[TBL] [Abstract][Full Text] [Related]
18. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
Hoshino K; Kikuchi E; Tanaka N; Akita H; Ito Y; Miyajima A; Jinzaki M; Oya M
Jpn J Clin Oncol; 2012 Mar; 42(3):202-7. PubMed ID: 22246718
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
20. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
